AndroGel Enhances BMD in Hypogonadal U.S. Men with Osteopenia: Randomized Trial
Reading Time: 2 minutes Introduction Osteopenia, characterized by reduced bone mineral density (BMD) but not yet meeting osteoporosis criteria, affects approximately 10 million American men, particularly those over 50 years of age. In the United States, age-related hypogonadism contributes significantly to this condition, with testosterone levels declining by 1-2% annually after age 30. AndroGel, a transdermal testosterone replacement therapy (TRT), has emerged as a promising intervention for restoring physiological androgen levels and potentially mitigating bone loss. This orthopedic study investigates the efficacy of AndroGel in improving BMD among American males diagnosed with osteopenia, drawing from a cohort of 250 participants across five U.S. medical...


